One site in Las Vegas has been shut down completely since May 2018.
NETSPOT ADVANCED ACCELERATOR APPLICATOINS GENERATOR
Some academic sites reported that the wait time for a generator was 14 to 18 months.Ĭommercial radiopharmacies are the largest consumers of GalliaPharm generators, according to the SNMMI, and AAA has found that some pharmacies have self-imposed blackouts of Netspot doses to extend the lifespan of their Ga-68 generators until replacements arrive. Netspot and Lutathera are designed to work together to diagnose and treat neuroendocrine tumors.Įach GalliaPharm generator is approved for 400 elutions (uses), and due to high Netspot demand, Eckert & Ziegler has been unable to keep up with demand for GalliaPharm since 2017. Netspot is the only FDA-approved isotope that uses gallium-68, and under the FDA approval, Netspot must be manufactured using GalliaPharm Ga-68 generators from Eckert & Ziegler.ĭemand for Netspot has increased with the approval in January 2018 of Lutathera, a therapeutic radiopharmaceutical also marketed by AAA. since the 2016 approval of Ga-68 DOTATATE (Netspot, Advanced Accelerator Applications ) for PET scans to localize NETs in adult and pediatric patients. In the letter, the SNMMI noted that the use of Ga-68 has increased in the U.S.
Food and Drug Administration (FDA) urging it to take steps to ease the shortage of the radioisotope gallium-68 (Ga-68) for use in PET to diagnose neuroendocrine tumors (NETs). SNMMI letter urges FDA to ease shortage of gallium-68 By Brian Casey, staff writerĪug- The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has written a letter to the U.S.
0 kommentar(er)
